Objective
Many therapeutic targets are shielded behind biological barriers, limiting the possibility to reach them with conventional drugs or diagnostic probes. Biological barriers are even more problematic for most biological pharmaceutics, such as recombinant proteins, antibodies and gene therapeutics. The most promising solution to this challenge is the use of nano-vehicles for specific targeting and delivery. The aim of NABBA is to form European early stage researchers (ESR) with cutting-edge scientific knowledge in the field of nanoparticles (NP) for biomedical application, able to cross biological barriers. For this aim the project will train ESRs, focusing on key aspects of nanobiotechnology: (i) design and chemical synthesis of different types of NPs, (ii) related techniques of detection and characterization, (iii) strategies of loading, targeting and delivery of drugs or diagnostic probes; (iv) proof of principle of pharmacological activity including pharmacokinetics and biodistribution. As a peculiar feature of NABBA, strong emphasis will be devoted to molecular mechanisms ruling biological barriers under physiological and pathological conditions, in order to develop novel nano-technological expedients for their crossing. Strong emphasis will be devoted to advanced chemistry issues, enabling new synthetic strategies either for NP assembly or functionalization. Different biological barriers will be addressed. ESRs will strongly benefit from a network of internationally recognized scientists in the field of chemistry, nanobiotechnology and nanomedicine, and the participation of companies with relevant interests and expertises in the field. The planned cooperation programs between Academia and Industries will allow the circulation of ESRs and this will give them the opportunity for to get acquainted with the most advanced research in the field, the most sophisticated technologies and the most advanced Industrial manufacturing platforms and innovative strategies.
Field of science
- /medical and health sciences/basic medicine/pathology
- /medical and health sciences/medical biotechnology/nanomedicine
- /medical and health sciences/clinical medicine/cancer/pancreatic cancer
- /medical and health sciences/basic medicine/immunology
Programme(s)
Call for proposal
H2020-MSCA-ITN-2014
See other projects for this call
Funding Scheme
MSCA-ITN-ETN - European Training NetworksCoordinator
20126 Milano
Italy
Participants (5)
75794 Paris
3584 CS Utrecht
15782 Santiago De Compostela
38124 Braunschweig
Participation ended
7632 Pecs
Partners (4)
8092 Zuerich
28003 Madrid
2100 Goedoello
4056 Basel